Heron Therapeutics shares are trading lower. The FDA acknowledged the receipt of the Company's Prior Approval Supplement application for ZYNRELEF.
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics shares are trading lower after the company announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement application for ZYNRELEF.
July 02, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Heron Therapeutics shares are trading lower following the announcement that the FDA has acknowledged the receipt of the company's Prior Approval Supplement application for ZYNRELEF.
The market reaction to the FDA's acknowledgment of the Prior Approval Supplement application for ZYNRELEF has been negative, leading to a decline in Heron Therapeutics' share price. This suggests investor concerns about the regulatory process or potential delays.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100